$450,000.00 in Sales Expected for Syros Pharmaceuticals Inc (NASDAQ:SYRS) This Quarter

Share on StockTwits

Analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to announce sales of $450,000.00 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $400,000.00 and the highest estimate coming in at $560,000.00. Syros Pharmaceuticals reported sales of $890,000.00 during the same quarter last year, which would suggest a negative year-over-year growth rate of 49.4%. The business is expected to report its next earnings report on Thursday, March 5th.

On average, analysts expect that Syros Pharmaceuticals will report full year sales of $1.93 million for the current financial year, with estimates ranging from $1.87 million to $2.03 million. For the next year, analysts expect that the company will report sales of $1.96 million, with estimates ranging from $1.60 million to $2.23 million. Zacks’ sales averages are an average based on a survey of analysts that follow Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%.

A number of analysts have recently commented on the company. BidaskClub upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 18th. Zacks Investment Research downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Piper Jaffray Companies decreased their price objective on Syros Pharmaceuticals from $24.00 to $18.00 in a report on Thursday, October 17th. Cowen reissued a “buy” rating on shares of Syros Pharmaceuticals in a research report on Tuesday, November 12th. Finally, ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $13.46.

In other Syros Pharmaceuticals news, insider Jeremy P. Springhorn purchased 9,879 shares of the stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $4.99 per share, for a total transaction of $49,296.21. Following the purchase, the insider now owns 24,879 shares of the company’s stock, valued at $124,146.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.80% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its stake in Syros Pharmaceuticals by 1.7% in the second quarter. JPMorgan Chase & Co. now owns 407,843 shares of the company’s stock valued at $3,242,000 after purchasing an additional 6,771 shares in the last quarter. Samsara BioCapital LLC grew its stake in shares of Syros Pharmaceuticals by 62.9% in the second quarter. Samsara BioCapital LLC now owns 1,726,603 shares of the company’s stock valued at $15,228,000 after buying an additional 666,665 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Syros Pharmaceuticals by 191.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,633,773 shares of the company’s stock worth $48,099,000 after buying an additional 3,044,728 shares during the last quarter. BlackRock Inc. increased its holdings in Syros Pharmaceuticals by 32.7% during the second quarter. BlackRock Inc. now owns 2,667,156 shares of the company’s stock worth $24,698,000 after buying an additional 656,735 shares during the last quarter. Finally, ARK Investment Management LLC increased its holdings in Syros Pharmaceuticals by 26.7% during the second quarter. ARK Investment Management LLC now owns 3,791,756 shares of the company’s stock worth $35,112,000 after buying an additional 799,056 shares during the last quarter.

SYRS stock traded down $0.04 during trading hours on Tuesday, reaching $4.60. 190,081 shares of the stock were exchanged, compared to its average volume of 235,109. The firm’s 50-day moving average is $5.23 and its 200-day moving average is $7.73. Syros Pharmaceuticals has a 12 month low of $4.53 and a 12 month high of $11.93. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.92 and a quick ratio of 4.92.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Read More: Balanced Fund

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.